Category Archives: NMPA

China Launches Electronic Customs Clearance Pilot for Imported Drugs at Beijing Port – NMPA and GACC Grant Digital Documents Equal Legal Force

Policy Snapshot

Item	Detail
Issuing Agencies	NMPA and General Administration of Customs of China (GACC)
Policy Type	Pilot program for electronic customs clearance documentation
Scope	Imported drugs, including medicinal crude materials (药材)
Pilot Location	Beijing Port
Effective Date	16 Sep 2026 (from date of announcement)
Legal Status	Electronic clearance documents have equal legal force with paper documents
Transition Arrangement	Paper documents remain valid during the pilot; enterprises may continue using them per existing regulations
Expansion Timeline	Not disclosed

Policy Details & Legal Framework

Objective: Further advance the digitalization of government services and improve the efficiency and convenience of customs clearance for imported drugs and medicinal materials.
Legal Parity: For the first time at the pilot port, electronic clearance documents are granted the same legal validity as paper documents — a critical enabler for fully digital cross-border pharmaceutical trade workflows.
Dual‑Track Transition: During the pilot period, the existing paper documentation remains valid, allowing importers to adopt the electronic channel at their own pace without operational disruption.
Joint Governance: The announcement was co‑issued by the drug regulator (NMPA) and the customs authority (GACC), reflecting cross‑agency coordination between product regulation and border control in pharmaceutical imports.

Industry Context

Legacy Paper Burden: Pharmaceutical imports into China have traditionally required paper‑based clearance certificates at ports of entry, adding administrative steps and courier logistics to time‑sensitive shipments.
Digital Trade Facilitation: The pilot aligns with China’s broader push to digitize government services and cross‑border trade documentation, including electronic customs declaration and paperless clearance reforms.
Inclusive Scope: By explicitly covering medicinal crude materials (药材) alongside finished drugs, the pilot addresses a segment historically subject to specialized port inspection requirements.
Strategic Entry Point: Beijing Port — served by Capital International Airport and Daxing International Airport cargo facilities — is a key gateway for imported pharmaceuticals, biologics, and temperature‑sensitive products.

Market Impact & Outlook

For Importers: Multinational pharmaceutical companies, distributors, and trading firms importing finished drugs, APIs, and herbal materials through Beijing can expect streamlined clearance procedures and reduced paperwork, lowering administrative costs.
Supply Chain Resilience: Electronic documentation reduces dependence on physical transport of clearance certificates, benefiting cold‑chain and urgent humanitarian shipments.
Regulatory Signal: The pilot may serve as a template for broader rollout to other major ports should it prove successful; no expansion timeline or additional ports have been disclosed.
Compliance Note: Enterprises operating dual‑track documentation should ensure internal systems can reconcile electronic and paper records during the transition period.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory implementation timelines, pilot expansion, and operational expectations for electronic customs clearance of imported drugs in China. Actual outcomes may differ due to factors including administrative execution at port level, enterprise adoption rates, and subsequent policy adjustments by the NMPA and GACC..-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260921091608111.html

NMPA Commissioner Huang Guo Inspects Tibetan Medicine Development in Xizang – Signals Push on Standards, Classical‑Formula Drug Conversion and Sustainable Sourcing

Inspection Milestone

Item	Detail
Delegation Head	Huang Guo – Party Secretary & Commissioner, NMPA
Locations	Lhasa and Shannan, Xizang Autonomous Region
Sites Visited	Pharmaceutical enterprises, medical institutions, grassroots market regulation departments, Tibetan medicinal‑material cultivation & breeding bases
Focus Areas	Tibetan medicine standard formulation/revision; new drug R&D; application of institutional preparations in medical facilities; grassroots drug regulation; production management of Tibetan medicinal materials
Participating Units	Heads of relevant NMPA departments and directly affiliated units
Stated Goal	Inherit, develop and utilize Tibetan medicine well – upholding both inheritance and innovation

Inspection Itinerary & Focus

Lhasa: The delegation visited pharmaceutical enterprises and medical institutions, examining in detail the formulation and revision of Tibetan medicine standards, new Tibetan drug R&D, and the clinical application of Tibetan medicine institutional preparations (hospital‑compounded formulations).
Shannan: The delegation inspected grassroots market regulation departments, pharmaceutical enterprises and Tibetan medicinal‑material cultivation and breeding bases, reviewing grassroots drug supervision, innovative drug development and production management of Tibetan medicinal materials.

Policy Directives Outlined

Standards Acceleration: Hasten the improvement of the Tibetan medicine standards system, leveraging the sector’s unique resource endowment and formulary experience.
Classical‑Formula Development: Intensify the development and utilization of ancient classical formulas, and promote the conversion of classical prescriptions and medical‑institution preparations into new drugs.
Three‑in‑One Evidence System: Deepen the application – in Tibetan new drug R&D – of the registration review evidence system that combines traditional Chinese medicine theory, human‑use experience and clinical trials, and strengthen communication and exchange across the entire R&D process.
Resource Protection & Sustainability: Strengthen the protection of Tibetan medicinal‑material resources, advance standardized (Good Agricultural Practice‑style) cultivation, ensure material quality and promote the sustainable development of Tibetan medicine.

Regulatory Context

Three‑Combined Evidence Pathway: The theory–human experience–clinical trial evidence framework was introduced nationally for traditional Chinese medicine registration, allowing human‑use experience to support drug applications – its explicit extension to Tibetan medicine lowers the evidentiary friction for ethnic‑medicine drug developers.
Institutional‑Preparation Pipeline: Hospital preparations with long clinical track records are a recognized seed pool for new drug conversion under China’s TCM reform agenda; Tibetan medicine institutions in Xizang hold sizable preparation portfolios.
Classical Formula Catalogs: Ancient classical formulas enjoy simplified registration pathways when developed per catalogue requirements, a mechanism the NMPA now seeks to activate for Tibetan formulary heritage.
Grassroots Supervision: Inspection of county‑level market regulation capacity signals attention to enforcement infrastructure for cultivation, processing and distribution quality of Tibetan medicinal materials.

Market Impact & Outlook

Ethnic‑Medicine Modernization: The inspection places Tibetan medicine high‑quality development squarely on the NMPA’s national agenda, likely catalyzing standards issuance, registration guidance and pilot programs for Xizang‑based enterprises.
R&D Opportunity Window: Developers able to package classical formulas or institutional preparations into registrable new drugs – supported by the three‑combined evidence system – gain a differentiated, policy‑endorsed pathway.
Supply‑Chain Upgrading: Emphasis on resource protection and standardized cultivation points to investment in GAP‑compliant cultivation and breeding bases, with implications for material quality, traceability and long‑term supply security.
Timeline & Measures: Specific policy instruments, funding and deadlines emerging from the inspection were not disclosed in the readout.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Tibetan medicine standard‑setting, classical‑formula drug conversion, registration evidence‑system application and cultivation standardization following the NMPA inspection in Xizang. Actual outcomes may differ due to risks including policy formulation timelines, registration review requirements, resource and supply‑chain conditions, and enterprise execution capabilities.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260911195710154.html

China’s CDE Opens Public Consultation on Technical Guidelines for Anti‑Tuberculosis Drug Clinical Trials – One‑Month Comment Window on Draft Framework

Regulatory Milestone

Item	Detail
Agency	Center for Drug Evaluation (CDE), NMPA (China)
Action Type	Public consultation on draft technical guideline
Document	Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs (Draft for Comments)
Purpose	Address the R&D needs of innovative anti‑TB drugs and standardize clinical trial design and conduct
Issue Date	9 September 2026
Comment Period	One month from publication (closing circa 9 October 2026)
Feedback Channels	zhaiy@cde.org.cn; chengjw@cde.org.cn
Next Steps	Revision and finalization of the guideline following review of public comments – detailed timeline Not disclosed

Guideline Scope & Policy Context

Objective: The draft was prepared by the CDE specifically “to meet the development needs of innovative anti‑pulmonary tuberculosis drugs,” signaling dedicated regulatory guidance for a therapeutic area historically underserved by tailored trial standards.
Consultation Approach: The CDE explicitly invites stakeholders across industry, academia, and the public to submit recommendations, with feedback to be incorporated in subsequent refinement of the guideline.
Specific Technical Provisions: Detailed trial design requirements, endpoint definitions, and population criteria in the draft – Not disclosed in the announcement itself; full text available via the CDE consultation posting.
Regulatory Pattern: The move extends China’s steady build‑out of disease‑specific technical guideline systems, giving sponsors earlier clarity on evidentiary expectations for anti‑TB clinical programs.

Clinical & Disease Context

Disease Burden: Tuberculosis remains among the world’s leading infectious‑disease causes of mortality, with China carrying one of the largest national TB burdens globally – underpinning sustained demand for innovative anti‑TB therapeutics.
Unmet Need: Drug‑resistant TB, lengthy treatment durations, and tolerability limitations of existing regimens continue to drive R&D toward new mechanisms and shorter, more effective combinations.
Trial Complexity: Anti‑TB trials involve distinct challenges – bacteriological endpoints, long follow‑up, relapse assessment, and combination‑regimen design – making standardized technical guidance a meaningful de‑risking tool for sponsors.

Market Impact & Outlook

Sponsor Implications: For domestic and multinational developers of anti‑TB candidates, finalized guidelines should reduce regulatory uncertainty in trial design and support more predictable review pathways in China.
Innovation Signal: Disease‑specific guidance reinforces the CDE’s broader policy direction of channeling structured support toward high‑unmet‑need infectious disease innovation.
Industry Participation: With a defined one‑month window, affected companies are expected to mobilize clinical, regulatory, and legal teams to shape provisions that will govern future TB trial submissions.
Final Guideline Timing: Publication date of the finalized version – Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization of the Technical Guidelines for Clinical Trials of Anti‑Tuberculosis Drugs, associated regulatory timelines, and the implications for clinical development programs. The draft remains subject to change based on public feedback; actual outcomes may differ due to regulatory, technical, and policy considerations.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/ed1b82a54ba2a669d8f1af21a100ce17